

## **RHINOMED RECEIVES \$280k RESEARCH AND DEVELOPMENT TAX REFUND**

**March 15th, 2017. Melbourne, Australia.**

Respiratory technology company Rhinomed Limited (ASX: RNO) has today received a Research and Development Tax Incentive refund of \$279,859 as part of the Australian Government's Research and Development Incentive Program for the 2016 financial year.

These funds reflect a \$621,911 investment in research and development used to advance the Company's sleep and respiratory technology platform, including its INPEAP device for obstructive sleep apnea.

The R&D Tax Incentive is a program jointly administered by the Australian Taxation Office and AusIndustry, under which companies receive a 45% refundable tax offset of expenditures on eligible research and development activities.

### **Media Enquiries**

Michael Johnson, CEO & Managing Director

+61 (03) 8416 0900

[mjohnson@rhinomed.global](mailto:mjohnson@rhinomed.global)

Follow us on **Twitter** @rhinomedceo @theturbinecom @mutesnoring

### **About Rhinomed Limited (ASX: RNO)**

Rhinomed Limited is a Melbourne based technology firm with a focus on nasal, respiratory and breathing management technologies. The company is monetising applications of its technology platform in the Sport, Sleep, Wellbeing and Drug Delivery markets. For more information go to

[www.rhinomed.global](http://www.rhinomed.global)